Emerald Mutual Fund Advisers Trust Boosts Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Emerald Mutual Fund Advisers Trust boosted its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 10.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 608,213 shares of the specialty pharmaceutical company's stock after buying an additional 58,525 shares during the quarter. Emerald Mutual Fund Advisers Trust owned approximately 1.22% of KalVista Pharmaceuticals worth $7,019,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in KALV. Aquatic Capital Management LLC bought a new position in KalVista Pharmaceuticals in the 4th quarter valued at approximately $44,000. GAMMA Investing LLC raised its holdings in KalVista Pharmaceuticals by 567.3% in the 1st quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock valued at $51,000 after buying an additional 3,767 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in KalVista Pharmaceuticals by 666.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after buying an additional 5,502 shares during the last quarter. Legal & General Group Plc raised its holdings in KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after buying an additional 1,494 shares during the last quarter. Finally, Martin Worley Group bought a new position in KalVista Pharmaceuticals in the 4th quarter valued at approximately $86,000.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 2,776 shares of KalVista Pharmaceuticals stock in a transaction on Monday, May 19th. The shares were sold at an average price of $11.84, for a total value of $32,867.84. Following the completion of the sale, the insider owned 106,611 shares in the company, valued at $1,262,274.24. The trade was a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Benjamin L. Palleiko sold 32,979 shares of KalVista Pharmaceuticals stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total transaction of $517,440.51. Following the completion of the sale, the chief executive officer directly owned 369,595 shares of the company's stock, valued at approximately $5,798,945.55. The trade was a 8.19% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 48,878 shares of company stock valued at $723,617 in the last quarter. 10.50% of the stock is currently owned by company insiders.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV traded down $0.05 during mid-day trading on Tuesday, hitting $15.17. The company had a trading volume of 1,419,723 shares, compared to its average volume of 578,698. The firm has a fifty day moving average price of $12.57 and a 200 day moving average price of $11.26. The company has a market capitalization of $757.74 million, a PE ratio of -4.11 and a beta of -0.04. KalVista Pharmaceuticals, Inc. has a one year low of $7.30 and a one year high of $16.32.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings data on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same quarter in the prior year, the company posted ($1.07) EPS. Research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on KALV. HC Wainwright raised their price objective on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Leerink Partners raised their price target on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a report on Monday, July 7th. Needham & Company LLC restated a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Jones Trading restated a "buy" rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Finally, JMP Securities raised their price target on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a report on Tuesday, July 8th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $26.29.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).